Cardiopulmonary Exercise Testing and Mortality Outcomes

Project: Research


  • Matthew Harber (PI)


The overall goal of this proposal is to enhance the prognostic resolution of cardiopulmonary exercise testing (CPX) on mortality risk prediction by examining the association among variables obtained during submaximal and maximal exertion CPX on all-cause, cardiovascular (CVD), and cancer mortality. The specific aims are to: 1. Examine the relationship between the gold-standard of directly measured cardiorespiratory fitness using respiratory gas exchange analysis (CPX-CRF) and all-cause, CVD, and cancer mortality. 2. Examine the independent relationship among submaximal and maximal CPX derived variables (ventilatory threshold [VO2 at VT], oxygen uptake efficiency slope [OUES], exercise ventilatory power [EVP], maximum ventilation [Ve], Ve-VCO2 slope, VO2-work rate relationship, circulatory power) and all-cause, CVD, and cancer mortality. 3. Evaluate the impact of adding submaximal and maximal CPX derived variables to CPX-CRF on mortality risk prediction models. And 4. Compare the prognostic resolution of CPX-CRF with CRF estimated from exercise tests and non-exercise prediction equations on all-cause, CVD, and cancer mortality. These aims will be examined in a cohort of 4137 self-referred, apparently healthy adult men and women, a demographic that has not been previously examined. Outcomes from this research will enhance the risk assessment efficacy of CPX and establish the significance of additional CPX variables to the prediction of longevity in apparently healthy adult men and women. The potential identification of submaximal CPX variables that can be objectively measured without maximal exertion should increase the feasibility of CPX. Further, this research will permit the development of objective age and sex specific thresholds of CRF, which may help guide clinical decisions. Collectively, these outcomes will expand the utilization of CPX in clinical practice.
Award amount$153,917.00
Award date04/01/2018
Program typeAHA Institutional Research Enhancement Award (AIRE
Award ID18AIREA33930023
Effective start/end date04/01/201806/30/2020